Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
This transaction is the third acquisition by three different Japanese players in this segment
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
